Healthcare stocks: 33 companies analyzed
The 33 healthcare and pharma companies Fintols covers, such as AbbVie, Abbott and Amgen: P/E, growth, margin and dividend with dated figures.
Healthcare spans drugmakers, biotech firms, medical device makers, diagnostics companies, health insurers, hospital operators and drug distributors. Pharmaceutical companies earn money by selling patented medicines, which for a period let them charge high prices without direct competition. Device makers sell equipment and, more importantly, the consumables and replacement parts that hospitals reorder again and again, while managed care companies collect premiums from employers, individuals and government programs. Distributors earn thin margins on enormous volumes of medicines.
With pharma and biotech, the essentials are the pipeline of drugs in development and when patents on the best-selling products expire, since losing that protection usually brings generics and a steep sales decline, often called a patent cliff. Look at R&D spending, gross margin and how diversified revenue is across products. For device makers, recurring consumables growth matters, while insurers and hospitals run on thin margins and heavy regulation. Many small biotechs have no profits yet, so check how much cash they have left.
Typical risks include failed clinical trials, regulatory rejections, lawsuits over side effects, government pressure on drug prices and patent expirations. If you’re starting out, it helps to focus on understanding companies with several products that rely less on any single outcome. A biotech with one drug in trials can double or collapse in a single day, which is closer to a bet than to an investment you can reason about. Spreading money across several companies lowers that specific risk considerably.
With data as of November 4, 2026, of the 33 healthcare and pharma companies Fintols covers, the largest by market value is Eli Lilly ($1.26 trillion) among those quoted in dollars and Sanofi (€100.8 billion) among those quoted in euros, the fastest-growing in its latest quarter is argenx (+52.1% in sales) and the highest dividend yield belongs to Pfizer (5.73%). The typical company in the group trades on a P/E of 31.3x and keeps a net margin of 14.9% (medians). Figures come from Yahoo Finance, the same source the Fintols analysis uses; N/A means the figure is not available.
Healthcare companies on Fintols
| Company | Market cap | P/E | Revenue growth | Net margin | Dividend yield |
|---|---|---|---|---|---|
| Eli Lilly (LLY) | $1.26 trillion | 46.0x | +38.6% | 31.9% | 0.49% |
| Johnson & Johnson (JNJ) | $665.2 billion | 41.9x | +5.9% | 16.2% | 2.01% |
| AbbVie (ABBV) | $521.0 billion | 50.7x | +10.3% | 15.7% | 2.42% |
| Merck (MRK) | $371.0 billion | 151.9x | +4.7% | 3.6% | 2.35% |
| UnitedHealth (UNH) | $367.5 billion | 23.4x | -0.4% | 3.5% | 2.29% |
| Thermo Fisher (TMO) | $261.6 billion | 37.2x | +9.1% | 14.9% | 0.27% |
| Amgen (AMGN) | $258.7 billion | 29.7x | +9.5% | 23.0% | 2.19% |
| Gilead (GILD) | $216.4 billion | N/A | +6.8% | -12.5% | 1.96% |
| Abbott (ABT) | $199.9 billion | 42.9x | +14.5% | 9.7% | 2.30% |
| Novo Nordisk (NVO) | $186.0 billion | 10.3x | +2.1% | 35.3% | 4.47% |
| Pfizer (PFE) | $175.5 billion | 44.0x | -0.4% | 6.3% | 5.73% |
| Intuitive Surgical (ISRG) | $170.3 billion | 58.3x | +21.7% | 25.5% | 0.00% |
| Danaher (DHR) | $165.2 billion | 38.9x | +8.3% | 16.9% | 0.70% |
| Vertex (VRTX) | $139.2 billion | 36.8x | +11.8% | 30.7% | 0.00% |
| Medtronic (MDT) | $134.3 billion | 25.8x | +13.7% | 13.9% | 2.91% |
| Bristol Myers Squibb (BMY) | $131.2 billion | 14.2x | +6.9% | 18.5% | 4.08% |
| Stryker (SYK) | $129.3 billion | 36.2x | +7.6% | 13.8% | 1.13% |
| HCA Healthcare (HCA) | $106.7 billion | 16.9x | +3.6% | 8.6% | 0.67% |
| Moderna (MRNA) | $103.2 billion | N/A | +2.1% | -141.4% | 0.00% |
| CVS Health (CVS) | $102.3 billion | 21.0x | +7.1% | 1.2% | 2.91% |
| Sanofi (SAN.PA) | €100.8 billion | 24.3x | +15.7% | 8.2% | 5.09% |
| Regeneron (REGN) | $96.3 billion | 20.6x | +36.3% | 28.5% | 0.39% |
| Elevance Health (ELV) | $94.2 billion | 18.4x | +1.4% | 2.5% | 1.66% |
| Cigna (CI) | $80.7 billion | 12.6x | +6.7% | 2.3% | 2.11% |
| Boston Scientific (BSX) | $66.4 billion | 19.3x | +1.4% | 16.6% | 0.00% |
| Edwards Lifesciences (EW) | $57.3 billion | 59.1x | +13.6% | 15.4% | 0.00% |
| Bayer (BAYN.DE) | €53.3 billion | N/A | +1.2% | -3.8% | 0.22% |
| argenx (ARGX.BR) | €51.3 billion | 32.8x | +52.1% | 31.7% | 0.00% |
| Humana (HUM) | $50.1 billion | 39.5x | +26.2% | 0.9% | 0.85% |
| Zoetis (ZTS) | $36.9 billion | 14.7x | -0.2% | 27.7% | 2.55% |
| Dexcom (DXCM) | $33.0 billion | 34.8x | +11.2% | 19.4% | 0.00% |
| Grifols (GRF) | €7.6 billion | 15.8x | +9.4% | 6.4% | 0.73% |
| Laboratorios Rovi (ROVI) | €3.3 billion | 17.6x | +20.0% | 24.0% | 1.52% |
Healthcare comparisons
- AbbVie vs Abbott
- AbbVie vs Amgen
- AbbVie vs Eli Lilly
- Abbott vs Amgen
- Abbott vs Eli Lilly
- Amgen vs Eli Lilly
- Bristol Myers Squibb vs CVS Health
- Bristol Myers Squibb vs Danaher
Other sectors
- Software and cloud
- Hardware and devices
- Semiconductor
- Internet and media
- Telecom
- Banking
- Financial services
- Insurance
- Consumer staples
- Retail
- Luxury and apparel
- Restaurant
- Automotive
- Energy
- Utility
- Industrial
- Aerospace and defense
- Travel and leisure
- Construction and infrastructure
- Materials
- Real estate (REIT)
See all stocks by sector or by index: S&P 500, S&P 100, IBEX 35 and Euro Stoxx 50. Educational content, not investment advice.